PENN VALLEY, PA, April 01, 2026 /24-7PressRelease/ -- Hector Barajas-Martinez, MSc, PhD, FHRS, has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Dr. Barajas-Martinez, a distinguished research professor at the Lankenau Institute for Medical Research Department of Cardiovascular Research, Main Line Health in Wynwood, Pennsylvania and Associate Professor at Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania. USA. Dr. Barajas-Martinez has established a prominent career in cardiovascular genetics and translational medicine of cardiogenetics. Since 2020, he has led efforts to identify genetic markers associated with sudden cardiac death syndromes, analyze inherited and familial cardiovascular disease cases within a comprehensive cardiogenetics program and translate genetic findings into laboratory-based mechanistic studies. His work investigates the molecular genetic backgrounds underlying lethal cardiac conditions, advancing understanding and developing potential cures and improved treatments for high-risk cardiovascular patients.

Prior to his current appointment, Dr. Barajas-Martinez served as a research associate professor at the Lankenau Institute for Medical Research in 2020. In this capacity, he continued to expand the institute's research portfolio by focusing on the identification of molecular heterogeneities recognized by experimental cardiology and molecular genetics teams at both electrical and genetic levels. His leadership contributed to the development of innovative approaches for diagnosing and treating inherited arrhythmogenic cardiac syndromes, using the new generation of genomics, gene expression and modulation in human, animal, stem cells models with cardiac arrhythmias.

From 2018 to 2020, Dr. Barajas-Martinez was a research scientist at the Lankenau Institute for Medical Research, where he played a pivotal role in translating genetic discoveries into clinical applications. His expertise in genetic diagnostics and mutational screening of ion channel genes—using Next Gen DNA sequencing and genotyping techniques—has been instrumental in improving outcomes for patients with Brugada syndrome, Short QT syndrome, Long QT syndrome, atrial fibrillation and other forms of sudden cardiac death syndromes.

Dr. Barajas-Martinez's earlier tenure at the Masonic Medical Research Laboratory in Utica, New York, spanned from 2007 to 2020. As a research scientist at both the Molecular Genetics and Cell Biology laboratories and its Cardiac Research Institute, he dedicated over a decade to exploring the genetic basis and molecular mechanisms underlying heart rhythm disorders. His work targeted the genetic foundations of inherited arrhythmogenic cardiac syndromes and fostered collaborations with national and international biomedical research centers addressing acquired and congenital heart rhythm disorders. Additionally, from 2010 to 2015, he contributed as a research scientist and director of Molecular Genetics in Cardiac Arrhythmias, further broadening his global perspective on cardiovascular genetics through collaborative projects across Europe, Asia and Latino America.

Throughout his career, Dr. Barajas-Martinez has demonstrated exceptional knowledge across chemistry, pharmacology, physiology and genetics. This multidisciplinary expertise enables him to interpret complex genetic data and assist individuals in need of genetic identification, a critical step in preventing hereditary cardiovascular problems that may be passed to future generations. His focus on identifying degenerative markers associated with autosomal dominant inheritance underscores his commitment to reducing the risk of transmission of these conditions.

Dr. Barajas-Martinez is recognized as an expert in cardiovascular genetics and translational medicine of cardiogenetics. He is an active member of several leading professional organizations, including the American Heart Association Inc., the Heart Rhythm Society, the Human Genome Organization, the American College of Cardiology Foundation, the American Physiological Society, National Health Institute, and the Biophysical Society. These affiliations have provided him with platforms to share his research findings and collaborate with peers worldwide.

His academic journey began in Guadalajara, Mexico, where he earned a doctorate in human genetics from Universidad de Guadalajara and University of Colima. The rigorous training he received under exceptional mentors ignited his passion for science in biophysics in ion channels linked with human physiology and pharmacology and laid the foundation for his future achievements. Dr. Barajas-Martinez has held certification as a laboratory director under CLIA from the Department of Health, State of New York from 2015-2025, a credential that underscores his commitment to maintaining high standards in clinical laboratory practice.

Dr. Barajas-Martinez's dedication to education extends beyond his own learning; he actively mentors' students from Drexel University, Thomas Jefferson University, Penn State University and Saint Joseph's University each year. He welcomes students from across the United States as well as Asia, Europe and South America into his laboratory, fostering a diverse environment that enriches scientific discovery. He values sharing knowledge through academic publications despite limited opportunities for specific work and strives to cultivate foundational understanding among emerging professionals.

Civic engagement is integral to his professional identity. He volunteers with Heart Walk initiatives organized by the American Heart Association Inc. and participates in fundraising efforts for genetic testing. Dr. Barajas-Martinez has also made significant scholarly contributions as author of more than 100 peer-reviewed articles indexed in PubMed, 5 book chapters and 6629 citations across disciplines such as human genetics, cardiac physiology, safety pharmacology and cardiogenetics. Notably, he authored "Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8," published in Heart Rhythm 2012; European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Heart Rhythm. 2022, Europace. 2022., and Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nat Genet. 2022. Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada Syndrome. Circulation, 2006., and Lidocaine-induced Brugada syndrome phenotype linked to a novel double mutation in the cardiac sodium channel. Circ Res. 2008.

Dr. Barajas-Martinez's contributions have been recognized through several prestigious awards: the Sharpe-Strumia Research Foundation Award; an additional award from the Woman's Board at Lankenau Medical Center, Main Line Health; and first prize at the Cardiogenetics Competition in Chicago hosted by the American Heart Association Inc.

Born in Guadalajara, Mexico, Dr. Barajas-Martinez enjoys reading fiction novels, hiking, playing soccer, swimming in the ocean and walking around in the river, beach in the Pacific Ocean, in the park during his personal time. He values spending time with his two sons and is dedicated to simplifying complex scientific concepts so they can appreciate the importance of his work.

Looking ahead, Dr. Barajas-Martinez envisions fostering innovation in academic research while cultivating new collaborative efforts both nationally and internationally, leading toward more integrated research teams within his field. He aims to establish guidelines for pharmacology studies related to genetic markers in sudden cardiac death syndromes while making meaningful contributions toward reducing mortality rates among individuals with cardiac disease.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #